Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
IPO Year: 2018
Exchange: NASDAQ
Website: equilliumbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/28/2025 | $3.00 → $1.00 | Outperform → Market Perform | Leerink Partners |
| 1/5/2022 | $18.00 → $14.00 | Outperform | SVB Leerink |
| 10/29/2021 | $12.00 | Buy | Stifel |
| 9/15/2021 | $14.00 | Overweight | Cantor Fitzgerald |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Equillium, Inc. (0001746466) (Issuer)
4 - Equillium, Inc. (0001746466) (Issuer)
4 - Equillium, Inc. (0001746466) (Issuer)
4 - Equillium, Inc. (0001746466) (Issuer)
4 - Equillium, Inc. (0001746466) (Issuer)
4 - Equillium, Inc. (0001746466) (Issuer)
4 - Equillium, Inc. (0001746466) (Issuer)
4 - Equillium, Inc. (0001746466) (Issuer)
4 - Equillium, Inc. (0001746466) (Issuer)
4 - Equillium, Inc. (0001746466) (Issuer)
Fastest customizable press release news feed in the world
LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Piper Sandler 37th Annual Healthcare ConferenceFormat:Fireside Chat & 1x1 MeetingsDate:Tuesday, December 2, 2025Time:11:30 AM EST Evercore ISI 8th Annual Healthcare ConferenceFormat:Fireside Chat & 1x1 MeetingsDate:Wednesday, December 3, 2025Time:3:50 PM EST Members of the Equillium management team will be available to participate in meetings w
Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal inflammation, the unmet medical need in ulcerative colitis, and the potential clinical utility of EQ504, a novel oral AhR modulator EQ504 Phase 1 clinical study initiation planned for mid-2026 LA JOLLA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial result
LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Stifel Healthcare Conference Format:Company Presentation & 1x1 MeetingsDate:Wednesday, November 12, 2025Time:3:20-3:50 PM EDT Jefferies Global Healthcare Conference in LondonFormat:1x1 MeetingsDate:Tuesday, November 18 – Thursday, November 20, 2025 Members of the Equillium management team will be available to participate in meetings with invest
LA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on October 31, 2025, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase a total of 7,200 shares of common stock to a new employee under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price per share equal to $1.41, Equ
LA JOLLA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced they will host a virtual key opinion leader (KOL) event on Wednesday, November 5, 2025, at 12:00 PM ET. The event will feature experts in their fields, Francisco J. Quintana, PhD (Harvard Medical School) and Brian Feagan, MD, FRCPC (Western Ontario), who will discuss the unmet needs and evolving treatment landscape in ulcerative colitis (UC) and the promise of targeting AhR to resolve inflammation and promote mucosal healin
LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced changes to its Board of Directors (BoD) and senior leadership, and other corporate updates. "The updates we announced today mark an important and timely step as we sharpen our therapeutic pipeline focus on advancing EQ504, our novel aryl hydrocarbon receptor (AhR) modulator, into the clinic to treat severe inflammatory diseases," said Bruce Steel, Chief Executive Officer at Equillium. "These changes are intended to strength
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M. Bradbury as Strategic and Metabolic Programs Advisor. "We are thrilled to welcome Dan to NeuraClick," said Dr. Subhi Marwari, Chief Executive Officer. "For an early-stage venture, experienced guidance is essential, and Dan's deep expertise in company building and metabolic therapeutics will be invaluable as we advance our pipeline. He is a phenomenal coach on this journey, helping us navigat
Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on August 29, 2025, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 150,000 shares of common stock to two new employees under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $1.74, Equillium's closing stock price on August 29,
Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Friday, September 5, 2025 at 7:55am ET. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation on the Events & Presentations page, located under the Investor Relations section on equilliumbio.com. An archived replay of both presentations will be available
Financing led by ADAR1 Capital Management and Janus Henderson Investors $30 million up front with the potential to receive an additional $20 million at clinical study initiation Phase 1 clinical study initiation planned mid-2026; data anticipated approximately 6 months thereafter Equillium, Inc. ("Equillium" or the "Company") (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it has entered into a definitive securities purchase agreement with leading healthcare investors that will provide up to $50 million in gross proceeds to Equillium. The private placement is comprised of (i) an initial upfront fi
S-3 - Equillium, Inc. (0001746466) (Filer)
10-Q - Equillium, Inc. (0001746466) (Filer)
8-K - Equillium, Inc. (0001746466) (Filer)
SCHEDULE 13G - Equillium, Inc. (0001746466) (Subject)
8-K/A - Equillium, Inc. (0001746466) (Filer)
8-K - Equillium, Inc. (0001746466) (Filer)
8-K - Equillium, Inc. (0001746466) (Filer)
424B5 - Equillium, Inc. (0001746466) (Filer)
EFFECT - Equillium, Inc. (0001746466) (Filer)
S-8 - Equillium, Inc. (0001746466) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Leerink Partners downgraded Equillium from Outperform to Market Perform and set a new price target of $1.00 from $3.00 previously
SVB Leerink reiterated coverage of Equillium with a rating of Outperform and set a new price target of $14.00 from $18.00 previously
Stifel resumed coverage of Equillium with a rating of Buy and set a new price target of $12.00
Cantor Fitzgerald initiated coverage of Equillium with a rating of Overweight and set a new price target of $14.00
Jonestrading initiated coverage of Equillium with a rating of Buy and set a new price target of $14.00
JonesTrading initiated coverage of Equillium with a rating of Buy and set a new price target of $14.00
Jonestrading initiated coverage of Equillium with a rating of Buy
HC Wainwright resumed coverage of Equillium with a rating of Buy and set a new price target of $12.00
Live Leadership Updates
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M. Bradbury as Strategic and Metabolic Programs Advisor. "We are thrilled to welcome Dan to NeuraClick," said Dr. Subhi Marwari, Chief Executive Officer. "For an early-stage venture, experienced guidance is essential, and Dan's deep expertise in company building and metabolic therapeutics will be invaluable as we advance our pipeline. He is a phenomenal coach on this journey, helping us navigat
Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and va
-Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in
Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the appointment of Barbara Troupin, M.D., to the Equillium Board of Directors. Dr. Troupin will serve as a member of the Nominating and Corporate Governance Committee of the Board. "We are very happy to welcome Dr. Barbara Troupin to the Equillium Board," said Dan Bradbury, chairman of the board of directors of Equillium. "Her experience building and leading clinical development, medical and regulatory affairs functions, as well as her background in global strategy and medical and com
LA JOLLA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Y. Katherine Xu, Ph.D., partner at Decheng Capital, has been appointed to Equillium’s board of directors, effective Thursday, February 4, 2021. “We’re excited to have Dr. Xu join the board of directors, as she brings with her a wealth of both scientific and Wall Street acumen,” said Dan Bradbury, executive chairman of the board of directors at Equillium. “Her addition complements the skills and experience of our board and her background will add a valuable perspective as Equ
LA JOLLA, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the appointment of Dolca Thomas, M.D., as its executive vice president of research and development and chief medical officer. Dr. Thomas joins Equillium from Principia Biopharma (recently acquired by Sanofi) where she was chief medical officer focused on developing treatments for immune-mediated diseases. “Equillium has made tremendous progress in 2020 and is now at a critical juncture as we begin to strategically outline more advanced development of itolizumab,” said Bruce Ste
Live finance-specific insights
Treatment with itolizumab did not improve complete or overall response rates at Day 29 Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of complete response and failure-free survival Breakthrough Therapy designation and meeting requests to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics
Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium's rights to itolizumab
Equillium grants Ono an option to purchase rights to itolizumab Equillium to receive an upfront payment of approximately $26.0M (¥3.5B); eligible to receive up to approximately $138.5M (¥18.7B) in option exercise and milestone payments Ono to fund Equillium's continued research and development of itolizumab during the exercise period Conference call and webcast today at 8:30 a.m. ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. ("Ono"), today announced an option and asset purchase agreement through which Ono gains the exclusive option to
Itolizumab demonstrates clinically meaningful response in highly proteinuric subjects: 5 of 6 (83%) subjects achieved complete or partial response and 4 of 6 (67%) subjects achieved > 80% reduction in urine protein creatinine ratio (UPCR) by week 28 8 of 12 (67%) subjects achieved > 50% reduction in UPCR (6 subjects still dosing) Itolizumab continues to demonstrate favorable safety and tolerability through six months of treatment Management will host a conference call and webcast today at 8:00 am ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical ne
Expected to add $33 million in cash at closing to Equillium's balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MHS, to be appointed to the Board of Directors Equillium, Inc. (NASDAQ:EQ) and Metacrine Inc. (NASDAQ:MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024.
Initiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD Acquired Bioniz Therapeutics, adding two first-in-class clinical-stage assets to pipeline and proprietary product discovery platform Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs. "It's been a transformative start to the year, leading to significant enhancements in how we are building value going forward," said Bruce Steel, chief executive office
Acquisition includes two first-in-class clinical-stage assets and proprietary product discovery platform Creates a robust immunology pipeline with significant value-creating milestones, and provides a strong clinical and research team with complementary expertise in immuno-inflammatory diseases Closing consideration of 5,699,492 shares of common stock of Equillium Equillium to host a conference call and webcast today at 8:00 a.m. Eastern Time Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has acquired Bioniz Therapeutic
This live feed shows all institutional transactions in real time.
SC 13G/A - Equillium, Inc. (0001746466) (Subject)
SC 13G - Equillium, Inc. (0001746466) (Subject)
SC 13G/A - Equillium, Inc. (0001746466) (Subject)
SC 13G/A - Equillium, Inc. (0001746466) (Subject)
SC 13G - Equillium, Inc. (0001746466) (Subject)
SC 13G/A - Equillium, Inc. (0001746466) (Subject)
SC 13D - Equillium, Inc. (0001746466) (Subject)
SC 13G/A - Equillium, Inc. (0001746466) (Subject)